C2N Diagnostics

C2N Diagnostics is a specialty diagnostics company focused on developing and commercializing novel diagnostics for Alzheimer's disease and related neurodegenerative disorders. Their mission is to improve treatment decisions and patients' lives by providing accurate and accessible diagnostic solutions. Their core technology relies on state-of-the-art mass spectrometry-based approaches to identify and quantify protein biomarkers that are important in the diagnosis, progression, and treatment monitoring of brain disorders.

C2N's flagship product is the PrecivityAD® and PrecivityAD2™ blood tests, which help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer's disease. These tests are designed to be less invasive and more accessible than traditional diagnostic methods like lumbar punctures and amyloid PET scans. C2N is also developing a comprehensive Brain Health Panel that will measure multiple features of AD and other neurological disorders, with the goal of providing even more comprehensive and informative diagnostic tools.

C2N Diagnostics does not mention job flexibility on their website or in their job postings.

C2N Diagnostics is a molecular diagnostics company focused on revolutionizing the early diagnosis and treatment of Alzheimer's disease and related neurodegenerative conditions. They aim to achieve this by developing and commercializing novel diagnostics, particularly blood-based tests, that provide healthcare providers with accurate and readily accessible tools to assess brain amyloid pathology and inform treatment decisions. Their mission is to improve patient care, accelerate clinical trials, and advance research by providing innovative and precise diagnostic solutions for brain health.

C2N Diagnostics fosters a culture of innovation and collaboration, driven by a shared mission to improve patient lives by transforming the early diagnosis and treatment of Alzheimer's disease and related neurodegenerative disorders. The company emphasizes cutting-edge research and development, attracting leading neurological scientists and researchers, and fostering a dynamic environment where scientific breakthroughs are celebrated. This collaborative approach extends to partnerships with academic institutions, pharmaceutical companies, and global organizations, further solidifying C2N's commitment to driving advancements in brain health diagnostics and therapeutics.